

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.415APPLICATION NO.
09/864,930SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Ronald BerensonFILING DATE
May 24, 2001GROUP ART UNIT
1644

FEB 10 2004

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,190,878	03/02/93	Wilhelm	435	285	
AB	5,443,983	08/22/95	Ochoa et al.	435	240.2	
AC	5,470,730	11/28/95	Greenberg et al.	435	172.3	
AD	5,672,505	09/30/97	Jones et al.	435	283.1	
AE	5,674,704	10/07/97	Goodwin et al.	435	69.1	
AF	5,735,279	04/07/98	Klaveness et al.	128	654	
AG	5,766,944	06/16/98	Ruiz	435	325	
AH	5,804,442	09/08/98	Romet-Lemonne et al.	435	374	
AI	5,837,477	11/17/98	Germain et al.	435	7.24	
AJ	5,858,358	01/12/99	June et al.	424	130.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
/	AK	EP 633930 B1	04/26/00	EPO		
/	AL	WO 97/01304	01/16/97	WIPO		
/	AM	WO 97/05233	02/13/97	WIPO		
/	AN	WO 97/05239	02/13/97	WIPO		
/	AO	WO 00/02520	01/20/00	WIPO <i>Duplicate</i>		X

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/	AP	Baroja, M.L. et al., "The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cell Activation with Immobilized Anti-CD3 and Mitogens," <i>Cellular Immunology</i> 120: 205-217, 1989.
/	AQ	Bergstresser, P.R. et al., "T Cell-Mediated Terminal Maturation of Dendritic Cells," in <i>Dendritic Cell in Fundamental and Clinical Immunology</i> , Ricciardi-Castagnoli (Ed.), Plenum Press, New York, 1997, pgs. 65-69.
/	AR	Bretscher, P., "The two-signal model of lymphocyte activation twenty-one years later," <i>Immunology Today</i> 13(2): 74-76, 1992.


EXAMINER

[Signature] 6/15/04

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.415		APPLICATION NO. 09/864,930	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson			
				FILING DATE May 24, 2001		GROUP ART UNIT 1644	


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE, IF APPROPRIATE
	BA	5,888,807	03/30/99	Palsson et al.	435	293.2
	BB	5,942,607	08/24/99	Freeman et al.	536	23.5
	BC	5,962,319	10/05/99	Ogawa et al.	435	325
	BD	5,972,721	10/26/99	Bruno et al.	436	526
	BE	5,985,653	11/16/99	Armstrong et al.	435	303.1
	BF	6,096,532	08/01/00	Armstrong et al.	435	286.5
	BG	6,113,901	09/05/00	Bluestone	424	154.1
	BH	6,129,916	10/10/00	Chang	424	179.1
	BI	6,143,297	11/07/00	Bluestone	424	184.1
	BJ	6,184,043	02/06/01	Fodstad et al.	436	526

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
			YES	NO
/ BK	WO 00/02520	01/20/00	WIPO	X
/ BL	WO 03/024312	03/27/03	WIPO	
/ BM	WO 03/025158	03/27/03	WIPO	
/ BN	WO 03/034820	05/01/03	WIPO	
/ BO	WO 03/043643	05/30/03	WIPO	
/ BP	WO 03/077658	09/25/03	WIPO	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/ BQ	Creson, J. et al., "The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro," <i>Journal Of Virology</i> , 73(11):9337-9347, November 1999.
/ BR	Groh, V. et al., "Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis," <i>Proceedings of the National Academy of Sciences</i> 100(16): 9452-9457, August 5, 2003.

EXAMINER <i>[Signature]</i> 6/15/04	DATE CONSIDERED
-------------------------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.415		APPLICATION NO. 09/864,930	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson			
				FILING DATE May 24, 2001		GROUP ART UNIT 1644	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
CA	6,197,298	03/06/01	Chang	424	179.1		
CB	6,316,257	11/13/01	Flyer et al.	435	372.3		
CC	6,352,694	03/05/02	June et al.	424	93.71		
CD	6,355,779	03/12/02	Goodwin et al.	530	388.23		
CE	2001/0031253	10/18/01	Gruenberg	424	93.1		
CF	2002/0090362	07/11/02	Stauss	424	93.21		
CG	2002/0182730	12/05/02	Gruenberg	435	375		
CH	2003/0039650	02/27/03	Gruenberg	424	144.1		
CI	2003/0134341	07/17/03	Gruenberg	435	7.21		
CJ	2003/0134415	07/17/03	Gruenberg	435	372		
CK	2003/0170238	09/11/03	Gruenberg et al.	424	144.1		
CL	2003/0175242	09/18/03	Gruenberg	424	93.2		
CM	2003/0175272	09/18/03	Gruenberg	424	144.1		
CN	2003/0194395	10/16/03	Gruenberg et al.	424	93.7		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION			
				YES	NO		
	CO						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
/	CP	Hami, L. et al., "Xcellerate™: A Platform Process for the GMP Manufacture of Activated T Cells for the Treatment of Patients with Cancer and Immune Dysfunction," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 1, abstract # 3630.					
/	CQ	Iezzi et al., "The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells," <i>Immunity</i> 8: 89-95, January 1998.					
EXAMINER <i>RZ</i> 6/15/04				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.415APPLICATION NO.
09/864,930SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Ronald BerensonFILING DATE
May 24, 2001GROUP ART UNIT
1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
DB					


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/	DC	June et al., "The B7 and CD28 receptor families," <i>Immunology Today</i> 15(7): 321-331, 1994.
/	DD	Kalamasz, D. et al., "Storage Shipment of Freshly Harvested or Cryopreserved Xcellerate™ Activated T Cells for Clinical Applications," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 2, abstract # 5113.
/	DE	Kato et al., "Gene Transfer of CD40-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells," <i>J. Clin. Invest.</i> 101(5): 1133-1141, March 1998.
/	DF	Krawczyk et al., "Cbl-b Is a Negative Regulator of Receptor Clustering and Raft Aggregation in T Cells," <i>Immunity</i> 13: 463-473, October 2000.
/	DG	Lanzavecchia, A., "The Role of Dendritic Cells in the Generation of Effector and Memory T Cell Responses," from <i>The Midwinter Conference of Immunologists</i> , January 22-25, 2000, available at www.midwconferimmunol.org/Midwinter00/sessions/lanzavecchia.html .
/	DH	Larsson, S. et al., "Productive Cytomegalovirus (CMV) Infection Exclusively in CD13-Positive Peripheral Blood Mononuclear Cells from CMV-Infected Individuals," <i>Transplantation</i> , 65(3):411-415, February 15, 1998.
/	DI	Li, Q. et al., "Expanded Tumor-reactive CD4 ⁺ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation," <i>Clinical Cancer Research</i> 5: 461-469, February 1999.
/	DJ	Li, Q. et al., "Immunological Effects of BCG as an Adjuvant in Autologous Tumor Vaccines," <i>Clinical Immunology</i> 94(1): 64-72, January 2000.
/	DK	Liebowitz et al., "Costimulatory approaches to adoptive immunotherapy," <i>Current Opinion in Oncology</i> 10: 533-541, 1998.
/	DL	Polanski, M. et al., "Xcellerate(: A Closed, Scalable Process for the GMP Manufacture of Stable Activated T Cells," in <i>Proceedings of the 15th Annual Scientific Meeting of the Society for Biological Therapy</i> , Seattle, October 26-29, 2000, and <i>Journal of Immunotherapy</i> , (23)5:599, September 2000.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DÉPARTEMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 980034.415		APPLICATION NO. 09/864,930	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Ronald Berenson			
				FILING DATE May 24, 2001		GROUP ART UNIT 1644	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
EA							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION	
						YES	NO
EB							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
/	EC	Ranheim and Kipps, "Activated T Cells Induce Expression of B7/BB1 on Normal or Leukemic B Cells through a CD40-dependent Signal," <i>J. Exp. Med.</i> 177: 925-935, April 1993.					
/	ED	Ten Berge et al., "Selective Expansion of a Peripheral Blood CD8 ⁺ Memory T Cell Subset Expressing Both Granzyme B and L-Selectin During Primary Viral Infection in Renal Allograft Recipients," <i>Transplantation Proceedings</i> 30: 3975-3977, 1998.					
/	EE	Zou, J.-P. et al., "Tumor-Bearing Mice Exhibit A Progressive Increase in Tumor Antigen-Presenting Cell Function and A Reciprocal Decrease in Tumor Antigen-Responsive CD4 ⁺ T Cell Activity," <i>The Journal of Immunology</i> 148(2): 648-655, January 15, 1992.					
	EF						
	EG						
	EH						
	EI						
	Ej						
	EK						
	EL						
EXAMINER  4/15/04				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							